Dynamic indices of fractalkine in ischemic stroke

Background. The problem of a personalized approach to patients with ischemic stroke does not lose its relevance. Research is being conducted aimed at searching for points of application in the pathogenesis of cerebral infarction and the possibility of influencing them in order to have a positive impact on the recovery prognosis of patients. The aim of the work. To study the level of fractalkine (FKN) in the blood serum of patients with ischemic stroke (atherothrombotic subtype) in dynamics. The data obtained in the future can serve as the basis for the possible use of fractalkine as one of the treatment options for patients with acute cerebral ischemia. Materials and methods. Sixty people took part in the study. Group I (control) – healthy people; Group II – patients with hypertensive crisis without signs of acute changes in target organs; Group III – patients with atherothrombotic pathogenetic subtype of ischemic stroke on the background of hypertensive crisis. Results. It was revealed that the level of fractalkine in patients with hypertensive crisis, and in patients on the first day after the development of ischemic stroke, was 3.2 times higher than in the control group (p < 0.001). The fractalkine content in the blood serum of patients with ischemic stroke remained high for ten days. The highest level was recorded on days 4–5 from the onset of the disease and exceeded the initial level by 27.5 % (p < 0.001). Positive correlations were established between fractalkine indicators and indicators of the NIHSS (National Institutes of Health Stroke Scale) and Rankin scales, and blood pressure (p < 0.001). Conclusion. Studying the role of fractalkine in the pathogenesis of cerebral infarction remains a promising direction. The results obtained with further research in this area may become the basis for the subsequent development of fundamentally new approaches in the treatment of patients with acute cerebral events.